MEDCOENERGI IMPROVES MSCI ESG RATING TO "AA"

2025-02-06 IDOPRESS

JAKARTA,Indonesia,Feb. 5,2025 -- PT Medco Energi Internasional Tbk (MedcoEnergi) has received an upgrade to its MSCI ESG rating,from "A" to "AA". This recognition positions MedcoEnergi as a leader in sustainability within the exploration and oil and gas industry.


Oyong Platform,East Java Asset

The MSCI ESG rating assesses companies based on their ability to manage ESG risks compared to industry peers. Companies are ranked asleaders (AAA,AA),average (A,BBB,BB),or laggards (B,CCC).Operating in a high-risk sector,MedcoEnergi has demonstrated strong ESG management,exceeding industry standards.

The company's latest rating upgrade is its third upgrade in five years,reflecting consistent enhancements in ESG performance. MedcoEnergi has strengthened its community development programs in the last five years and issued standalone Human Rights Policy in 2024. The company is also advancing its emission reduction initiatives in line with its Net Zero commitments for Scope 1 and 2 by 2050,and Scope 3 by 2060. Additionally,MedcoEnergi has maintained a Total Recordable Injury Rate well below the International Association of Oil & Gas Producers (IOGP) overall and Asia/Australasia regional averages.

"This upgrade to'AA' from MSCI acknowledges our sustainability efforts and reinforces our commitment to integrating ESG into all aspects of our operations," saidHilmi Panigoro,President Director of MedcoEnergi.

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.

Newest

1Cangxi County Holds 2026 New Year's Cultural Performance for the Public

Cangxi County Holds 2026 New Year's Cultural Performance for the Public

2The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

3The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

4Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

5Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

6Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

©copyright 2009-2020 Singapore Info Map